BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28675638)

  • 21. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
    Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
    Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
    Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Brunet S; Bergua J; Tormo M; García-Boyero R; Sarrà J; Del Potro E; Grande C; Barba P; Bernal T; Amigo ML; Grau J; Cervera J; Feliu E;
    Leuk Lymphoma; 2017 Jan; 58(1):145-152. PubMed ID: 27122129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96).
    Isoyama K; Eguchi M; Hibi S; Kinukawa N; Ohkawa H; Kawasaki H; Kosaka Y; Oda T; Oda M; Okamura T; Nishimura S; Hayashi Y; Mori T; Imaizumi M; Mizutani S; Tsukimoto I; Kamada N; Ishii E
    Br J Haematol; 2002 Sep; 118(4):999-1010. PubMed ID: 12199778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch.
    Nakajima K; Kubota H; Kato I; Isobe K; Ueno H; Kozuki K; Tanaka K; Kawabata N; Mikami T; Tamefusa K; Nishiuchi R; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
    Cancer Sci; 2022 Jul; 113(7):2472-2476. PubMed ID: 35467057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.
    Rice S; Roy A
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194564. PubMed ID: 32376390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Cheng YF; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    Ann Hematol; 2021 May; 100(5):1267-1281. PubMed ID: 33712867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
    Yang L; Ding L; Liang J; Chen J; Tang Y; Xue H; Gu L; Shen S; Li B; Chen J
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27266. PubMed ID: 29943896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of constitutive activation of FMS-related tyrosine kinase-3 and
    Fedders H; Alsadeq A; Schmäh J; Vogiatzi F; Zimmermann M; Möricke A; Lenk L; Stadt UZ; Horstmann MA; Pieters R; Schrappe M; Stanulla M; Cario G; Schewe DM
    Haematologica; 2017 Nov; 102(11):e438-e442. PubMed ID: 28838992
    [No Abstract]   [Full Text] [Related]  

  • 30. Romidepsin enhances the efficacy of cytarabine
    Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
    Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical and molecular biologic characteristics of 36 cases of leukemia with 11q23/mll].
    Zhao J; Yin YM; Zhao YL; Sun Y; Wang JB; Zhong J; Zhang X; Fei XH; Shan FX; Liu HX; Wang T; Wang H; Tong CR; Wu T; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1381-5. PubMed ID: 21176334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23);
    Du J; Chisholm KM; Tsuchiya K; Leger K; Lee BM; Rutledge JC; Paschal CR; Summers C; Xu M
    Pediatr Dev Pathol; 2021; 24(4):378-382. PubMed ID: 33749383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?
    Mansur MB; Ford AM; Emerenciano M
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):521-526. PubMed ID: 29056538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia.
    Breese EH; Krupski C; Nelson AS; Perentesis JP; Phillips CL
    J Pediatr Hematol Oncol; 2021 May; 43(4):152-154. PubMed ID: 32496443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
    Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pediatric case of
    Murphy L; Siegele B; Carstens B; Hartman L; Faulk K
    Leuk Lymphoma; 2024 Jun; 65(6):843-847. PubMed ID: 38372299
    [No Abstract]   [Full Text] [Related]  

  • 37. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
    Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
    [No Abstract]   [Full Text] [Related]  

  • 39. Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
    Wander P; Cheung LC; Pinhanҫos SS; Jones L; Kerstjens M; Arentsen-Peters STCJM; Singh S; Chua GA; Castro PG; Schneider P; Dolman MEM; Koopmans B; Molenaar JJ; Pieters R; Zwaan CM; Kotecha RS; Stam RW
    Leukemia; 2020 Nov; 34(11):2898-2902. PubMed ID: 32488115
    [No Abstract]   [Full Text] [Related]  

  • 40. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.